Transparency Disclosure Roundtable

April 2014

pwc

Introduction of Facilitators

Sarah Otten

Senior Director, Corporate Compliance, Vertex Pharmaceuticals Inc. (United States)

Ekaterina Walloe

Competency Development Professional, Clinical Operations, Novo Nordisk (Denmark)

Mike McNeal

Director, PwC Global Pharmaceutical and Life Sciences Advisory (United States)

Bharathram Lakshmivarahan

Director, PwC Global Pharmaceutical and Life Sciences Advisory (United States)

1. What is your strategy for tracking cross border spend?

2. How are you approaching the R&D reporting requirements?

3. How do you plan to address the issue of data privacy and consent?

4. How are companies approaching / managing globalization of master data?

What extra considerations are you taking to include HCOs?

5. How do you plan to manage / structure your program?

Will it be mainly facilitated globally (centralized), regionally, (an EU team) or at the country level?

Outsource or Insource; what part?

6. What new processes or policies do you think will arise from the new requirements?

7. What do you think the public's expectations are with HCP transaction reporting?

8. Are tax implications being considered as part of your Transparency disclosure strategy?

Thank You

Sarah Otten

Senior Director, Corporate Compliance, Vertex Pharmaceuticals Inc. (United States)

sarah_otten@vrtx.com

Ekaterina Walloe

Competency Development Professional, Clinical Operations, Novo Nordisk (Denmark)

eksw@novonordisk.com

Mike McNeal

Director, PwC Global Pharmaceutical and Life Sciences Advisory (United States)

mike.mcneal@us.pwc.com

Bharathram Lakshmivarahan

Director, PwC Global Pharmaceutical and Life Sciences Advisory (United States)

bharathram.lakshmivarahan@us.pwc.com